Triple-Drug cocktail aims to extend life in tough stomach cancer

NCT ID NCT07309185

Recruiting now Disease control Sponsor: Shandong Tumor Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether adding two drugs (adebrelimab and famitinib) to standard chemotherapy (irinotecan) can help people with advanced stomach or gastroesophageal junction cancer whose first treatment stopped working. About 66 participants will be randomly assigned to receive either the three-drug combo or irinotecan alone. The main goal is to see if the combo delays cancer growth.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Adebrelimab, famitinib malate, and irinotecan
What this could lead to: If successful, this combination could offer a new treatment option for advanced gastric cancer patients who have run out of standard options.
What could go wrong: This is a small, early-phase exploratory study with only 66 participants, so results may not apply broadly. The combination also carries risks of side effects from multiple drugs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED GASTRIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastric neoplasm gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

STOMACH NEOPLASMS

Contacts and locations

Locations

Shandong First Medical University Affiliated Cancer Hospital
RECRUITING

Jinan, Shandong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.